PlainPatent
USPTO 2015–2025 USPTO PatentsView US Corporation

Kezar Life Sciences, Inc.

USPTO PatentsView assignee record - 9 granted patents across 6 technology areas, recorded in grant years 2020–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

RSS updates for this company
Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Kezar ranks #29,205 of 49,997 tracked US assignees by granted-patent volume, with 9 patents across 6 technology areas.

#29,205
of 49,997 US assignees by volume
Top 19%
by Innovation Score (47.4/100)
18.0
avg claims per patent

USPTO PatentsView assignee plate

Corpus R29205 · US Corporation #29,205 · 9 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH

  • GRANTS-MICRO 9 grants
  • MID-PACK #29,205/49,997
  • PHOTO-FINISH KCI Medical…
  • CPC-NARROW C07D · 6 areas
  • INNOV-PAR 47.4/100
  • CLAIMS-RICH 18.0 claims/avg
  • TYPE-USCORP US Corporation
  • SPAN-YRS 2020–2025 · 6y
  • BOOK-RICH 9/10 fields

Nearest grant-volume peer: KCI Medical Resources Unlimited Company (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Kezar’s 47.4 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Kezar

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Kezar's Innovation Score is 47.4/100 (top 19% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Kezar?

Each dot is one of Kezar’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Kezar’s own 18.0 claims/patent is ABOVE the 15.2 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Kezar vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 8.98.999.1 51015202530 Granted patents (volume) Avg claims / patent KCI Medical Resources Unlimited Company - 9, 19.22KCI Medical Resou…Keene Building Products Co., Inc. - 9, 15.11Keene Building Pr…KEY Energy Services, LLC - 9, 20.11KEY Energy Servic…Keyview Labs, Inc. - 9, 19.56Keyview LabsKezzler AS - 9, 14.56Kezzler ASKingfar International Inc. - 9, 9.33Kingfar Internati…Kirusa, Inc. - 9, 28.44KirusaKJ Chemicals Corporation - 9, 15.22KJ ChemicalsKezar Life Sciences, Inc. - 9, 18Kezar Life Scienc…
Kezar vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Kezar's grants concentrate

Kezar Life Sciences, Inc. is a focused PatentsView assignee: 6 CPC subclasses with 77.8% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2022 (3 grants) versus a trough of 1 in 2023. By volume, Kezar sits between KCI Medical Resources Unlimited Company and KJ Chemicals Corporation.

Kezar's three-year grant acceleration

Kezar Life Sciences, Inc. shows 6 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Kezar's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Kezar holds 9 patents at rank #29,172, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Kezar

By rank, the assignees closest to #29,172 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Kezar's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Kezar, neither rank-band nor same-CPC leaders (those blocks stay above). In C07D (Heterocyclic Compounds), Kezar ranks #1,096 of 3,165 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (47 here).

Limin' Innovations LLC 47 Ncsoft Corporation 47 Renmatix, Inc. 47 Danfoss Commercial Compressors 47

Kezar's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

47 Top 19% higher than 81% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.533.5 20202022202320242025 1
USPTO utility patent grants by year · 2020–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table
Kezar Life Sciences, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2020 2 22.2%
2022 3 33.3%
2023 1 11.1%
2024 2 22.2%
2025partial year 1 11.1%

Which technologies does Kezar Life Sciences, Inc. patent most?

Top 6 of 6 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Kezar Life Sciences, Inc.'s patent record in context - here's where to go next.

  • Kezar Life Sciences, Inc.'s lead technology class is C07D (Heterocyclic Compounds), 77.8% of its portfolio - see every assignee active in that class. Explore C07D
  • Ranked #29,205 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Kezar Life Sciences, Inc. against KCI Medical Resources Unlimited Company, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 47.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.